EANS-News: Annual General Meeting of Marseille-Kliniken AG supports positive development of the company

--------------------------------------------------------------------------------
Corporate news transmitted by euro adhoc. The issuer/originator is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

Annual & Special Corporate Meetings

Subtitle: - New supervisory board member Prof. Dr. Enderlein elected
- Expansion of the authorized capital to € 18.7 million - At the
request of the administration former board members were not relieved

Hamburg (euro adhoc) - 27 January 2012 - Today´s Annual General
Meeting, located at the company´s headquarter in Hamburg, approved
all significant applications of the administration with a majority of
over 90 percent. This represented approximately 65 percent of the
share capital.

On administration´s recommendation, both former directors, Stefan
Herzberg and Dr. Thomas Klaue, were not relieved. Prof. Dr. Dietmar
Enderlein was elected to the Supervisory Board. The long-time expert
in the health care industry is following Mathias Kampmann, who
retired on 17 January 2012.

The decision on the creation of new authorized capital was supported
by the major shareholder and the representatives of shareholder
protection communities. Overall, the meeting took place under the
close observation of journalists and numerous experts in health care.

"The decisions of our shareholders will create a reliable basis for
our operational success.", said Michael Thanheiser, chairman of the
company.

Further inquiry note:
Christian Hillermann
Hillermann Consulting
Investor Relations for Marseille-Kliniken AG
Poststraße 14/16
20354 Hamburg
Germany
Tel.: +49-(0)40 / 320 279-10
Fax: +49-(0)40 / 320 279-114
www.marseille-kliniken.com

end of announcement euro adhoc
--------------------------------------------------------------------------------

company: Marseille-Kliniken AG
Alte Jakobstraße 79/80
D-10179 Berlin
phone: +49 (0)30 246 32-400
FAX: +49 (0)30 246 32-401
mail: info@marseille-kliniken.de
WWW: http://www.marseille-kliniken.de
sector: Pharmaceuticals
ISIN: DE0007783003
indexes: CDAX, Classic All Share, Prime All Share
stockmarkets: free trade: Berlin, Düsseldorf, Stuttgart, regulated dealing:
Hamburg, regulated dealing/prime standard: Frankfurt
language: English